Maxcyte (MXCT) Depreciation Expense (2024 - 2026)

Maxcyte (MXCT) has 3 years of Depreciation Expense data on file, last reported at $1.0 million in Q1 2026.

• Quarterly Depreciation Expense fell 5.16% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (down 1.38% YoY) and the FY2025 annual result came in at $4.3 million, down 0.65% from the prior year.
• Depreciation Expense fell to $1.0 million in Q1 2026 per MXCT's latest filing, from $1.1 million in the prior quarter.
• Across five years, Depreciation Expense topped out at $1.1 million in Q2 2025 and bottomed at $1.0 million in Q1 2026.
• The 3-year median for Depreciation Expense is $1.1 million (2024), against an average of $1.1 million.
• The widest annual swing landed in 2025, when Depreciation Expense increased 0.74%; it then dropped 5.16% in 2026.
• Tracing MXCT's Depreciation Expense over 3 years: stood at $1.1 million in 2024, then declined by 0.19% to $1.1 million in 2025, then slipped by 2.37% to $1.0 million in 2026.
• Per Business Quant, the three latest MXCT Depreciation Expense figures stand at $1.0 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025).

Peer Comparison